Get the Stockscreener App
0.9677
1.79%
-0.0225
Prokidney Corp stock is traded at $0.9677, with a volume of 586.52K.
It is down -1.79% in the last 24 hours and down -3.71% over the past month.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.
See More
Previous Close:
$0.9902
Open:
$1
24h Volume:
586.52K
Relative Volume:
0.85
Market Cap:
$102.45M
Revenue:
-
Net Income/Loss:
$-35.47M
P/E Ratio:
-1.6977
EPS:
-0.57
Net Cash Flow:
$-124.27M
1W Performance:
+22.96%
1M Performance:
-3.71%
6M Performance:
-44.43%
1Y Performance:
-64.11%
1-Day Range:
$0.944
$1.03
1-Week Range:
$0.6574
$1.03
52-Week Range:
$0.4603
$4.44
Prokidney Corp Stock (PROK) Company Profile
Name
Prokidney Corp
Sector
Industry
Phone
336-999-7028
Address
2000 FRONTIS PLAZA BLVD., WINSTON-SALEM
Compare PROK with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PROK
Prokidney Corp
|
0.9651 | 102.45M | 0 | -35.47M | -124.27M | -0.57 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.40 | 125.74B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
599.66 | 61.57B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
613.01 | 36.40B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.49 | 30.36B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
245.06 | 24.89B | 3.81B | -644.79M | -669.77M | -6.24 |
Prokidney Corp Stock (PROK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-30-24 | Initiated | JP Morgan | Neutral |
| Sep-10-24 | Initiated | Guggenheim | Buy |
| Mar-07-24 | Resumed | Morgan Stanley | Equal-Weight |
| Jan-02-24 | Downgrade | BofA Securities | Buy → Neutral |
| Jul-25-23 | Initiated | BTIG Research | Buy |
| Dec-21-22 | Initiated | Jefferies | Buy |
| Nov-10-22 | Initiated | Morgan Stanley | Equal-Weight |
| Oct-18-22 | Initiated | UBS | Buy |
| Oct-14-22 | Initiated | Citigroup | Buy |
| Sep-23-22 | Initiated | BofA Securities | Buy |
| Sep-02-22 | Initiated | Evercore ISI | Outperform |
View All
Prokidney Corp Stock (PROK) Latest News
ProKidney Corp (NASDAQ:PROK)’s 12-Month Price Target Currently Stands At 6 - Marketing Sentinel
Major Investment Alert: Carso De-C Inmobiliaria Acquires ProKidney Shares! - TipRanks
ProKidney Corp [PROK] Records 50-Day SMA of $1.0283 - knoxdaily.com
The Psychology of ProKidney Corp Inc. (PROK) Price Performance: Understanding Market Sentiment - investchronicle.com
Analytical Overview: ProKidney Corp (PROK)’s Ratios Tell a Financial Story - DWinneX
The ProKidney Corp (PROK) had a good session last reading, didn’t it? - uspostnews.com
Major Investment Alert: ProKidney Stock Sees New Stakeholder! - TipRanks
Major Investment Alert: ProKidney Stock Acquisition! - TipRanks
Major Investment Alert: ProKidney Stock Sees Significant Purchase! - TipRanks
Greensboro’s Once Great Win Is Now A ProKidney Failure - The Rhino Times of Greensboro -
Major Investment Alert: ProKidney Stock Sees Big Buy-In! - TipRanks
Control empresarial de capitales purchases $628,847 in ProKidney shares - Investing.com
Control empresarial de capitales purchases $628,847 in ProKidney shares By Investing.com - Investing.com Canada
Sei Investments Co. Makes New $69,000 Investment in ProKidney Corp. (NASDAQ:PROK) - Defense World
Critical Review: Candel Therapeutics (NASDAQ:CADL) & ProKidney (NASDAQ:PROK) - Defense World
PROK stock touches 52-week low at $0.49 amid market challenges - Investing.com India
Institutional owners may take dramatic actions as ProKidney Corp.'s (NASDAQ:PROK) recent 32% drop adds to one-year losses - simplywall.st
Bank of New York Mellon Corp Has $388,000 Holdings in ProKidney Corp. (NASDAQ:PROK) - Defense World
Here's Why We're Watching ProKidney's (NASDAQ:PROK) Cash Burn Situation - Yahoo Finance
Down -38% in 4 Weeks, Here's Why You Should You Buy the Dip in PROKIDNEY CP (PROK) - Yahoo Finance
PROK stock touches 52-week low at $0.94 amid market challenges - Investing.com India
ProKidney Corp reports results for the quarter ended December 31Earnings Summary - TradingView
ProKidney Hold Rating: Balancing Developmental Progress and Financial Stability Amid Uncertainty - TipRanks
ProKidney Corp (PROK) Reports $163.3 Million Net Loss for 2024, - GuruFocus.com
ProKidney reports larger loss in 2024 as production resumes - Winston-Salem Journal
PROKIDNEY CORP. SEC 10-K Report - TradingView
ProKidney CEO cites 'significant progress' after regenerative medicine company loses $163M in 2024 - The Business Journals
ProKidney reports FY24 EPS (62c), consensus (59c) - TipRanks
ProKidney Corp. Reports 2024 Financial Results and Milestones in Rilparencel Development for Chronic Kidney Disease - Nasdaq
ProKidney Reports Full Year 2024 Financial Results and Business Highlights - GlobeNewswire
FDA Fast-Tracks ProKidney's CKD Treatment: $358M War Chest Fuels Breakthrough Development - StockTitan
Top 3 Health Care Stocks You'll Regret Missing This Quarter - Benzinga
ProKidney (PROK) Expected to Announce Quarterly Earnings on Thursday - Defense World
ProKidney (NASDAQ:PROK) Stock Price Down 2.7%Here's What Happened - MarketBeat
ProKidney stock hits 52-week low at $1.34 amid market challenges - Investing.com Australia
ProKidney stock hits 52-week low at $1.34 amid market challenges By Investing.com - Investing.com South Africa
Head to Head Review: ProKidney (NASDAQ:PROK) and Adaptimmune Therapeutics (NASDAQ:ADAP) - Defense World
Owning 32% shares,institutional owners seem interested in ProKidney Corp. (NASDAQ:PROK), - Yahoo
ProKidney Corp (NASDAQ: PROK) Has Great Upside Potential - Stocks Register
ProKidney Corp [PROK] Chief Regulatory Officer makes an insider sale of 16,412 shares worth 41,030. - Knox Daily
JPMorgan Chase & Co. Purchases 18,472 Shares of ProKidney Corp. (NASDAQ:PROK) - Defense World
Kuehn Law Encourages Investors of ProKidney Corp. to Contact Law Firm - The Malaysian Reserve
2025 Will Be A Major Year For ProKidney’s Rilparencel In CKD Treatment (NASDAQ:PROK) - Seeking Alpha
US Penny Stocks: 3 Picks With Market Caps Under $300M - Simply Wall St
ProKidney secures out-of-market buyer, $20.5 million price tag for Greensboro site - The Business Journals
ProKidney's high-profile Greensboro plant initiative ends with planned $20 million sale of property - Winston-Salem Journal
ProKidney (NASDAQ:PROK) Trading 8.7% HigherStill a Buy? - MarketBeat
Prokidney Corp Stock (PROK) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):